GBM-Derived Wnt3a Induces M2-Like Phenotype in Microglial Cells Through Wnt/β-Catenin Signaling.
Glioblastoma
M2-like phenotype
Microglia
Wnt/β-catenin pathway
Wnt3a
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
09
04
2018
accepted:
23
05
2018
pubmed:
28
6
2018
medline:
12
7
2019
entrez:
28
6
2018
Statut:
ppublish
Résumé
Glioblastoma is an extremely aggressive and deadly brain tumor known for its striking cellular heterogeneity and capability to communicate with microenvironment components, such as microglia. Microglia-glioblastoma interaction contributes to an increase in tumor invasiveness, and Wnt signaling pathway is one of the main cascades related to tumor progression through changes in cell migration and invasion. However, very little is known about the role of canonical Wnt signaling during microglia-glioblastoma crosstalk. Here, we show for the first time that Wnt3a is one of the factors that regulate interactions between microglia and glioblastoma cells. Wnt3a activates the Wnt/β-catenin signaling of both glioblastoma and microglial cells. Glioblastoma-conditioned medium not only induces nuclear translocation of microglial β-catenin but also increases microglia viability and proliferation as well as Wnt3a, cyclin-D1, and c-myc expression. Moreover, glioblastoma-derived Wnt3a increases microglial ARG-1 and STI1 expression, followed by an upregulation of IL-10 mRNA levels, and a decrease in IL1β gene expression. The presence of Wnt3a in microglia-glioblastoma co-cultures increases the formation of membrane nanotubes accompanied by changes in migration capability. In vivo, tumors formed from Wnt3a-stimulated glioblastoma cells presented greater microglial infiltration and more aggressive characteristics such as growth rate than untreated tumors. Thus, we propose that Wnt3a belongs to the arsenal of factors capable of stimulating the induction of M2-like phenotype on microglial cells, which contributes to the poor prognostic of glioblastoma, reinforcing that Wnt/β-catenin pathway can be a potential therapeutic target to attenuate glioblastoma progression.
Identifiants
pubmed: 29948952
doi: 10.1007/s12035-018-1150-5
pii: 10.1007/s12035-018-1150-5
doi:
Substances chimiques
CTNNB1 protein, human
0
WNT3A protein, human
0
Wnt3A Protein
0
beta Catenin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1517-1530Références
J Neurosci. 2001 Mar 15;21(6):2028-38
pubmed: 11245686
BMC Cancer. 2013 Nov 10;13:537
pubmed: 24209998
Biochim Biophys Acta. 2007 May;1773(5):642-52
pubmed: 16926057
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Endocr Metab Immune Disord Drug Targets. 2015;15(2):105-18
pubmed: 25772168
J Neurosci. 2017 Feb 15;37(7):1772-1784
pubmed: 28077724
Mol Cell Neurosci. 2013 May;54:44-57
pubmed: 23337036
PLoS One. 2016 Dec 9;11(12):e0165118
pubmed: 27936099
Neuroscience. 2012 Jan 3;200:130-41
pubmed: 22062133
Biotechnology. 1992;24:145-9
pubmed: 1422008
Connect Tissue Res. 2015;56(5):414-25
pubmed: 26291921
J Neuroimmunol. 2014 Sep 15;274(1-2):71-7
pubmed: 25042352
Front Oncol. 2017 Jul 10;7:143
pubmed: 28740831
J Neuropathol Exp Neurol. 2005 Sep;64(9):754-62
pubmed: 16141784
Oncol Rep. 2017 Sep;38(3):1341-1352
pubmed: 28714013
Adv Exp Med Biol. 2016;949:245-261
pubmed: 27714693
Differentiation. 2006 Dec;74(9-10):562-72
pubmed: 17177853
Crit Rev Oncog. 2007 Nov;13(2):93-158
pubmed: 18197790
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17406-11
pubmed: 16293698
J Immunol. 1992 Mar 1;148(5):1404-10
pubmed: 1538124
Oncogene. 2006 Dec 14;25(59):7747-57
pubmed: 16799642
Front Surg. 2016 Mar 02;3:11
pubmed: 26973839
BMC Neurosci. 2012 Nov 23;13:144
pubmed: 23173708
Glia. 2011 Jan;59(1):119-31
pubmed: 20967887
Curr Top Med Chem. 2012;12(19):2082-93
pubmed: 23167797
Nature. 2009 Jan 22;457(7228):389-90
pubmed: 19158779
Crit Rev Oncog. 2014;19(5):327-36
pubmed: 25404148
Glia. 2012 Jan;60(1):96-111
pubmed: 21989594
Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):31-45
pubmed: 26708597
Cancer Res. 1990 Oct 15;50(20):6683-8
pubmed: 2208133
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):333-340
pubmed: 28554667
BMC Cancer. 2014 Dec 08;14:923
pubmed: 25482099
Eur Biophys J. 2008 Feb;37(2):121-9
pubmed: 17598104
Brain Behav Immun. 2016 Jul;55:225-235
pubmed: 26593276
J Neurosci Res. 2013 Sep;91(9):1143-51
pubmed: 23686747
Exp Cell Res. 2015 Dec 10;339(2):280-8
pubmed: 26511503
Acta Neurochir (Wien). 1997;139(7):619-24
pubmed: 9265954
Oncol Lett. 2015 Oct;10(4):2442-2446
pubmed: 26622867
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Life Sci. 2011 Oct 10;89(15-16):545-54
pubmed: 21635906
J Clin Oncol. 2007 Sep 10;25(26):4127-36
pubmed: 17827463
Neurotherapeutics. 2017 Apr;14(2):372-384
pubmed: 28374184
Genes Cells. 1998 Oct;3(10):659-70
pubmed: 9893023
Front Mol Biosci. 2017 Jul 18;4:50
pubmed: 28770210
Front Oncol. 2017 Jun 16;7:120
pubmed: 28670569